{
  "question": "之前我有做过人流，有奶水了，涨疼时自己就挤了，不过都一年多了，最近这段时间乳房突然疼痛，而且能挤出像奶水一样的液体，但确定不是奶水，不会是乳腺癌吧，我好担心，都不敢去医院，希望你能给分析分析……谢谢",
  "retrieved_context": "",
  "ai_answer": "retrieved_context: [\n    {\n      \"content\": \"Oncogenic activation of RAS/MAPK is associated with a significant reduction in tumor-infiltrating lymphocytes (TILs) and lower survival in TNBC patients, while concomitant MEK inhibition and antiPD1/PD-L1 immunotherapy augmented anti-tumor immunity in preclinical TNBC models (Loi et al., 2016)In addition to the ERK pathway, MAP3K1 can regulate MAPK-JNK signaling through phosphorylation of substrates such as MAP2K4Relatively frequent somatic mutations occur in MAP2K4 and MAP3K1 in luminal cancers (12% in total), often coincident with PIK3CA mutationsWhile JNK pathway activation is predictive of chemotherapy sensitivity in TNBC, recent evidence suggests JNK signaling fosters an immunosuppressive TME to drive tumor progression, implicating JNK-targeted immunotherapy as a potential treatment strategy for TNBC (Semba et al., 2022). Cyclin D1-CDK4/6-RB axis The cyclin D1-CDK4/6-RB axis is the pivotal regulator of the G1-S transition of the cell cycle\",\n      \"title\": \"Deciphering breast cancer_ from biology to the clinic.pdf\"\n    },\n    {\n      \"content\": \"n engl j med 375;8 nejm.org August 25, 2016 719 70-Gene Signature in Early Breast Cancer clinical and genomic results were advised not to receive adjuvant chemotherapy, whereas patients who were categorized as having high-risk disease by both tests were advised to receive chemotherapy. Patients with discordant results (i.e., either high clinical risk and low genomic risk or low clinical risk and high genomic risk) were randomly assigned to the chemotherapy group or the no-chemotherapy group on the basis of either the clinical result or the genomic resultThe treatment randomization used a minimization technique that was stratified according to institution, risk group, hormone-receptor status (ER-positive or progesterone [PR]-positive vs ER-negative and PR-negative), nodal involvement (yes or no), age (<50 years vs≥50 years), HER2 status (HER2-positive vsHER2-negative vsunknown), axillary treatment (sentinel node only vs dissection), and type of surgery (mastectomy vs\",\n      \"title\": \"CSCO BC指南参考文献29.pdf\"\n    },\n    {\n      \"content\": \"Many other reviews reached similar conclusions, reporting positive moderate effect sizes of mind-body interventions on anxiety and distress in cancer.45, 98 Risk/Benefit assessment of meditation interventions: Meditation therapies pose very little risk to participants in this type of interventionFew adverse events have been reported in any trials, but there has been recent interest within the meditation research community in exploring adverse reactions to intensive meditation practice, particularly in vulnerable individuals.99, 100 Typically, potential participants are screened through individual orientation interviews prior to joining meditation group programs, and participants who have serious mental health issues are often re-directed to individual counseling or psychiatric intervention prior to or concomitant with mind-body intervention participation\",\n      \"title\": \"Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment.pdf\"\n    },\n    {\n      \"content\": \"If more than 50% of the constituent items on the QLQ-C30 and QLQ-BR23 scales were completed, a prorated score was computed.17 For scales with less than 50% of the items completed, the scale was considered missing. Mean change of the linear transformed scores from baseline—and SEs—were computed for each assessment timepoint. RESULTS From June 2014 to June 2015, 444 patients were randomly assigned (T-DM1+P, n = 223; TCH+P, n = 221; Fig 1 and Appendix Table A1, online only), and all but two patients in the TCH+P arm received one or more dose of study medication.12 Baseline characteristics were balanced between arms (Appendix Table A2, online only)Hormone receptor–positive disease was present in 62.2% of patients, and 83.1% had clinical stage IIA to IIIA disease, 66.4% were white, and 25.2% were Asian\",\n      \"title\": \"CSCO BC指南参考文献11.pdf\"\n    },\n    {\n      \"content\": \"Both groups also received concurrent intravenous trastuzumab, with an initial loading dose of 8 mg/kg and a maintenance dose of 6 mg/kg on day 1, as well as intravenous pertuzumab with a loading dose of 840 mg and a maintenance dose of 420 mg on day 1 This report is the final analysis of the primary endpoint, pathological complete response (ypT0/is ypN0), analysed in all patients who started treatment (modified intention to treat)The trial is registered with ClinicalTrials.gov, NCT04547907, and follow-up of the adjuvant phase is ongoing. Findings Between Sept 20, 2020, and March 1, 2023, 789 patients were screened for eligibility, 689 of whom were randomly assigned (343 to the nab-paclitaxel group and 346 to the docetaxel plus carboplatin group)All 689 patients were Asian women669 patients received at least one dose of the study treatment and were included in the full analysis set (332 in the nab-paclitaxel group and 337 in the docetaxel plus carboplatin group)\",\n      \"title\": \"CSCO BC指南参考文献13.pdf\"\n    },\n    {\n      \"content\": \"Recently, a new subclass of malignant cells within tumors called the cancer stem cells (CSCs) are observed and associated with tumor initiation, escape and recurrenceThis small population of cells, which may develop from stem cells or progenitor cells in normal tissues, have self-renewal abilities and are resistant to conventional therapies such as chemotherapy and radiotherapy [13-15]Breast cancer stem cells (bCSCs) were first identified by Ai Hajj and even as few as 100 bCSCs could form new tumors in the immunocompromised mice [16]bCSCs are more likely to originate from luminal epithelial progenitors rather than from basal stem cells [17]Signaling pathways including Wnt, Notch, Hedgehog, p53, PI3K and HIF are involved in the self-renewal, proliferation and invasion of bCSCs [18-21]\",\n      \"title\": \"Risk Factors and Preventions of Breast Cancer.pdf\"\n    }\n  ]\n抱歉，我暂时无法回答此问题，请咨询专业医师。",
  "ref_answer": "如果在非哺乳期和非孕期有溢液一般为乳房疾病的表现。主要疾病有，乳腺导管扩张症。乳管内乳头状瘤。乳房囊性增生。乳腺癌。出现症状要及时到医院就诊，做溢液涂片细胞学检查，近红外线乳腺扫描，B超、钼靶等检查，确定病情后进行治疗",
  "context_relevance": 0.22518739104270935,
  "faithfulness": 0.23896309733390808,
  "answer_relevance": 0.4794284701347351,
  "answer_correctness": 0.45155030488967896,
  "context_recall": 0.0,
  "rag_score_mean": 0.2790258526802063
}